Editas wins clearance to start first-in-human EDIT-401 trial

Editas Medicine said it has received approval to initiate a first-in-human Phase 1/2 clinical trial of EDIT-401 in patients with hyperlipidemia who require additional LDL-C lowering. The clearance allows the company to begin dosing, marking the program’s transition from preclinical development into human testing.

The trial is an early step, not evidence of efficacy or safety in patients. The immediate change is operational: EDIT-401 can now generate clinical data in the population it is intended to treat, with future readouts expected to determine whether the program advances beyond initial testing.

For Editas, the program adds a clinical development milestone to a business that reported $40.5 million of revenue for fiscal 2025, up 25.4% year over year, alongside a net margin of -395.0% and diluted EPS of $-1.80. Those figures describe the prior annual period and do not measure EDIT-401’s clinical performance.

The key uncertainties are the trial’s safety profile, the magnitude and durability of LDL-C lowering, and the pace of enrollment and dosing. No patient outcomes have yet been established by the approval to start the study.

Next, investors will look for the first dosing update and subsequent Phase 1/2 data, particularly safety findings and changes in LDL-C. The timing of those disclosures and the company’s funding needs for continued development remain open questions.